Intra-Cellular's CAPLYTA (lumateperone) Receives the US FDA's Approval for the Treatment of Schizophrenia in Adults
Shots:
- The approval is based on the study assessing CAPLYTA (42 mg) vs PBO while keeping Positive and Negative Syndrome Scale (PANSS) as 1EP
- The study resulted in somnolence/sedation (24% vs.10%) and dry mouth (6% vs. 2%)
- CAPLYTA is a once-daily- oral therapy mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors
Click here to read full press release/ article | Ref: Intra-Cellular | Image: Behance
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com